Close Menu

NEW YORK (GenomeWeb) – Guardant Health announced today a multiyear agreement with AstraZeneca to develop blood-based companion diagnostic tests for drugs in the pharma firm's oncology portfolio.

Under the terms of the agreement, Guardant is developing and pursuing FDA approval for a companion test that will help identify non-small cell lung cancer patients likely to respond to Tagrisso (osimertinib), AstraZeneca’s third-generation EGFR inhibitor.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.